NASDAQ · REGN
Regeneron Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for REGN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $13.76 | $15.06 | $12.83 | 6 |
| Dec 2026 | $17.55 | $23.76 | $12.83 | 6 |
| Mar 2027 | $10.66 | $11.78 | $9.11 | 3 |
| Jun 2027 | $12.47 | $13.08 | $11.90 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Zacks · RTTNews · Barchart- BNK Invest · Oct 29, 10:52 AM EDTNoteworthy ETF Outflows: JEPQ, ISRG, VRTX, REGNLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Nasdaq Equity Premium Income ETF (Symbol: JEPQ) where we have detected an approximate $156.2 million dollar outflow — that's a 0.4% decrea
- Zacks · Oct 28, 10:20 AM EDTAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
- Zacks · Oct 26, 9:00 AM EDTAnalysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forJazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 8:40 AM EDTHere's Why Regeneron (REGN) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- RTTNews · Oct 26, 7:33 AM EDTRegeneron Extends BARDA Agreement For Additional Ebola Treatment Supply(RTTNews) – Regeneron Pharmaceuticals (REGN) announced an extension of its agreement with the U.S. Biomedical Advanced Research and Development Authorities (BARDA) to provide additional supplies of Inmazeb, the company's approved Ebola treatment, for U.S. preparedness efforts.
- RTTNews · Oct 26, 2:35 AM EDTRegeneron Reports Long-Term Phase 3 Benefit For Libtayo In High-Risk CSCC(RTTNews) – Regeneron Pharmaceuticals, Inc. (REGN) announced longer-term data from the Phase 3 C-POST trial, which includes nearly four years of follow-up, evaluating the PD-1 inhibitor Libtayo (cemiplimab) as adjuvant treatment for patients with high-risk cutaneous squamous cell
- Zacks · Oct 23, 9:00 AM EDTRegeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseRegeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Barchart · Oct 21, 2:24 PM EDTStocks Finish Mostly Higher on Earnings OptimismThe S&P 500 Index ($SPX ) (SPY ) closed up by +0.38% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.13%. December E-mini S&P futures (ESZ26 ) rose +0.33%, and December E-mini…
- BNK Invest · Oct 21, 10:57 AM EDTIBB, REGN, NTRA, ARGX: Large Outflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an approximate $200.0 million dollar outflow — that's a 1.8% decrease week over week
- Barchart · Oct 20, 6:45 PM EDTStocks Pressured by Tech Stock Weakness and Higher Crude Oil PricesThe S&P 500 Index ($SPX ) (SPY ) is down by -0.15% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. December E-mini S&P futures (ESZ26 ) are down -0.10%, and December E-mini…
- Barchart · Oct 20, 6:14 PM EDTStocks Rebound on Strong Earnings and Lower Bond YieldsThe S&P 500 Index ($SPX ) (SPY ) is up by +0.60% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.12%. December E-mini S&P futures (ESZ26 ) are up +0.60%, and December E-mini…
- The Motley Fool · Oct 19, 10:44 AM EDTForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketRegeneron’s leading weight-loss candidate could offer patients an option with fewer side effects.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Regeneron Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.